Why have molecular drivers for cancer therapy been embraced by the oncology community in China, and what role does NGS testing and genomic profiling currently play in decision-making?

Why have molecular drivers for cancer therapy been embraced by the oncology community in China, and what role does NGS testing and genomic profiling currently play in decision-making?

Why have molecular drivers for cancer therapy been embraced by the academic oncology community in China, and what role does NGS testing and comprehensive genomic profiling—such as that provided by FoundationOne and other laboratories—currently play in clinical decision-making?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Janice Tsang, MBBS, MRCP(UK), FRCP (Lond.)

Janice Tsang, MBBS, MRCP(UK), FRCP (Lond.)

Specialist in Medical Oncology
Hon. Clinical Assistant Professor
Li Ka Sing Faculty of Medicine
The University of Hong Kong